新型三敲除异体BCMA CAR-T(CT0590)治疗多发性骨髓瘤的临床前及I期研究
该研究为临床前加I期首次人体试验,纳入5例患者(4例RRMM、1例pPCL),评估装甲NKG2A CAR的异体BCMA CAR-T(CT0590)。CT0590耐受良好,无剂量限制毒性、治疗相关死亡或GVHD。3例获确认缓解,其中2例达sCR,RRMM患者sCR持续>23个月。
要点
- CT0590为HLA-I缺陷、BCMA靶向并装甲NKG2A CAR的异体CAR-T,可抵抗宿主NK细胞杀伤。
- 5例中3例缓解、2例达sCR;RRMM者sCR>23个月,pPCL者sCR持续20个月。
- 未观察到剂量限制毒性、治疗相关死亡或GVHD。
核心结论
- CAR-NKG2A技术可能克服宿主抗移植物反应(HVGR),尤其在NK细胞NKG2A表达升高的患者中。
- CT0590在RRMM和pPCL中值得进一步研究。
研究设计与样本
- 临床前体外及动物研究评估异体CAR-NKG2A T细胞抗宿主NK细胞杀伤能力。
- 首次人体I期研究纳入5例患者:4例复发难治多发性骨髓瘤(RRMM)、1例原发性浆细胞白血病(pPCL)。
- 试验注册号NCT05066022。
主要发现
- 体外和动物研究显示异体CAR-NKG2A T细胞有效抵抗宿主NK细胞介导的杀伤。
- BCMA/NKG2A双靶向异体CAR-T(CT0590)在临床前体内模型中显示强抗肿瘤活性。
- CT0590耐受良好,无剂量限制毒性、治疗相关死亡或移植物抗宿主病(GVHD)。
- 3例患者获确认缓解,其中2例达严格完全缓解(sCR)。
- RRMM患者sCR在数据截止时仍持续(缓解持续时间>23个月),pPCL患者sCR持续20个月。
临床怎么用
- 对RRMM和pPCL患者,CT0590可能提供异体CAR-T治疗选择并避免GVHD。
- 患者基线NK细胞NKG2A表达可能有助于筛选获益人群。
局限性
- 样本量小(5例),结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Host-versus-graft reaction (HVGR) is a major challenge in allogeneic chimeric antigen receptor (CAR) T-cell therapy. To counter host natural killer (NK) cell attacks, we armored allogeneic, HLA-I-deficient, B-cell maturation antigen (BCMA)-targeting CAR T cells with an NKG2A CAR. In vitro and animal studies demonstrated that allogeneic CAR-NKG2A T cells effectively resisted host NK cell-mediated killing. BCMA and NKG2A dual-targeting allogeneic CAR T cells (CT0590) resisted killing by NK cells and showed robust antitumor activity in preclinical in vivo models. On the basis of these data, a first-in-human study enrolled 5 patients (4 with relapsed and refractory multiple myeloma [RRMM] and 1 with primary plasma cell leukemia [pPCL]). CT0590 was well tolerated and caused no dose-limiting toxicities, treatment-related death, or graft-versus-host disease. Three patients achieved confirmed responses, including 2 with stringent complete response (sCR). Notably, sCR in the patient with RRMM was still ongoing (duration of response >23 months) at the time of data cutoff, and sCR in the patient with pPCL lasted for 20 months. Both patients showed robust expansion of universal CAR T cells (maximum concentration of >280 000 copies per μg genomic DNA) and higher baseline NKG2A expression on NK cells than nonresponders. These results suggest that CAR-NKG2A technology may overcome HVGR, especially in patients with elevated NKG2A expression on NK cells. Further studies of CT0590 in RRMM and pPCL are warranted. This trial was registered at www.clinicaltrials.gov as NCT05066022.
引用
- Jin S, Liao Z, Yan S, et al. A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood. 2026. PMID: 42275247. doi:10.1182/blood.2025032112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。